• MeSH
• Aminoglycosides administration & dosage   adverse effects   MeSH
• Anti-Bacterial Agents * administration & dosage   classification   adverse effects   MeSH
• Endocarditis * etiology   drug therapy   complications   physiopathology   MeSH
• Gram-Negative Bacteria pathogenicity   MeSH
• Humans MeSH
• Rifampin administration & dosage   MeSH
• Vancomycin administration & dosage   adverse effects   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Practice Guideline MeSH

x

x

• MeSH
• Amoxicillin administration & dosage   therapeutic use   MeSH
• Anti-Bacterial Agents therapeutic use   MeSH
• Debridement methods   MeSH
• Prosthesis-Related Infections * surgery   therapy   MeSH
• Clindamycin administration & dosage   therapeutic use   MeSH
• Humans MeSH
• Replantation methods   MeSH
• Rifampin administration & dosage   adverse effects   therapeutic use   MeSH
• Aged MeSH
• Check Tag
• Humans MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Case Reports MeSH

• MeSH
• Antibiotics, Antitubercular administration & dosage   therapeutic use   MeSH
• Mycobacterium Infections, Nontuberculous * diagnosis   drug therapy   transmission   MeSH
• Hypothyroidism chemically induced   MeSH
• Drug Interactions MeSH
• Middle Aged MeSH
• Humans MeSH
• Mycobacterium marinum pathogenicity   MeSH
• Fish Diseases transmission   MeSH
• Finger Injuries pathology   MeSH
• Rifampin administration & dosage   therapeutic use   MeSH
• Thyroxine administration & dosage   therapeutic use   MeSH
• Zoonoses MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Publication type
• Case Reports MeSH

Hidradenitis suppurativa (acne inversa) je chronické, zánětlivé, recidivující, vysilující kožní onemocnění, které se projevuje postpubertálně bolestivými, hluboko uloženými, zánětlivými lézemi v oblastech, kde jsou lokalizovány apokrinní potní žlázy, nejčastěji v axilách, inguinách a anogenitálně (Dessau definice, 1st International Conference on Hidradenitis suppurativa, 30. 3.–1. 4. 2006, Dessau, Německo). Hidradenitis suppurativa je velmi závažné onemocnění s četnými komplikacemi, komorbiditami a s refrakterními následky pro pacienta, ale bývá bohužel často chybně nebo velmi pozdě diagnostikováno. Postiženo je 1 % populace, projevuje se nejčastěji od puberty do 50. roku věku a častěji jsou postiženy ženy. Primární patologický proces je lokalizován do oblasti terminálního vlasového folikulu s následným postižením apokrinních potních žláz. Klinicky nacházíme komedony (jedno/vícepórové), bolestivé hluboce uložené zánětlivé noduly, abscesy, drénující sinusy, jizvení a sekundární lymfedém. Dle tíže klinického obrazu dělíme pacienty do tří stupňů Hurleyho klasifikace, dále se používají k hodnocení léčby dynamické skórovací systémy. V roce 2015 byly vydány Evropské S1 doporučené postupy pro léčbu hidradenitis suppurativa/acne inversa a následně terapeutický algoritmus pro léčbu onemocnění, který dělí terapii na první linii (lokální klindamycin 1%; systémová antibiotika: tetracyklin – doxycyklin, rifampicin + klindamycin; adalimumab), druhou linii (infliximab, acitretin, glukonát zinku, resorcinol, intralezionální glukokortikoidy) a třetí linii léčby (kolchicin, botulotoxin, isotretinoin, dapson, cyclosporin, hormonální terapie – antiandrogeny). Dále má nezastupitelnou roli v léčbě chirurgie a adjuvantní terapie. Mezioborová spolupráce je důležitá v celostním přístupu k hidradenitis suppurativa.

Hidradenitis suppurativa or acne inversa is a chronic, inflammatory, reccurent, debilitating skin disease that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the body, most commonly the axillaries, inguinal and anogenital regions (Dessau definiton, 1st International Conference on Hidradenitis suppurativa, March 30-April1, 2006, Dessau, Germany). Hidradenitis suppurativa is very serious illness with certain complications and comorbidities and refractory results for the patients, but unfortunatelly it is still either lately or misdiagnosed. Prevalence is 1% of population. It starts after puberty and the incidence declines after fifth decade. Women are more prone to hidradenitis suppurativa. Primary patological proces is localised to the terminal hair follicle with ongoing apocrine gland involvement. Clinically we see comedones, painfull deep-seated inflamed nodules, abscesses, draining sinuses, scarring, secondary lymphedema. Hurley scale devides the patients into three stages according to the clinical picture. Other dynamic scaling systems are used. In 2015 were printed European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa, followed by therapeutical algorithm, which devides therapeutical options into three lines: 1st line (topical clindamycin 1%; systemic anibiotics: tetracyclin - doxycyclin, clindamycin + rifampicin; adalimumab), 2nd line (infliximab, acitretin/etretinate, zinc gluconate, resorcinol, intralesional glucocorticoids) and 3rd line (colchicine, botulinum toxinum, isotretinoin, dapson, cyclosporin, hormonal therapy – antiandrogens). Adjuvant therapy and surgery is necessary. Multidisciplinary attititude is important for the therapeutical outcome.

• MeSH
• Acitretin administration & dosage   MeSH
• Adalimumab administration & dosage   MeSH
• Pain etiology   drug therapy   MeSH
• Botulinum Toxins, Type A therapeutic use   MeSH
• Cyclosporine therapeutic use   MeSH
• Dapsone therapeutic use   MeSH
• Dermatologic Surgical Procedures methods   MeSH
• Child MeSH
• Adult MeSH
• Hidradenitis Suppurativa * diagnosis   drug therapy   classification   MeSH
• Clindamycin administration & dosage   pharmacology   MeSH
• Colchicine therapeutic use   MeSH
• Lasers, Gas therapeutic use   MeSH
• Humans MeSH
• Resorcinols administration & dosage   pharmacology   MeSH
• Rifampin administration & dosage   pharmacology   MeSH
• Zinc Compounds administration & dosage   MeSH
• Severity of Illness Index MeSH
• Tertiary Healthcare organization & administration   statistics & numerical data   MeSH
• Triamcinolone administration & dosage   MeSH
• Patient Care Team MeSH
• Drug Administration Routes MeSH
• Check Tag
• Child MeSH
• Adult MeSH
• Humans MeSH
• Publication type
• Review MeSH

• MeSH
• Antitubercular Agents * MeSH
• Ethambutol administration & dosage   therapeutic use   MeSH
• Isoniazid administration & dosage   therapeutic use   MeSH
• Humans MeSH
• Tuberculosis, Multidrug-Resistant MeSH
• Pyrazinamide administration & dosage   therapeutic use   MeSH
• Rifampin administration & dosage   therapeutic use   MeSH
• Streptomycin administration & dosage   therapeutic use   MeSH
• Tuberculosis * drug therapy   therapy   MeSH
• Check Tag
• Humans MeSH

• MeSH
• Analgesics MeSH
• Anticoagulants MeSH
• Anticonvulsants MeSH
• Antitubercular Agents MeSH
• Cycloserine MeSH
• Ethambutol administration & dosage   therapeutic use   MeSH
• Proton Pump Inhibitors MeSH
• Isoniazid administration & dosage   therapeutic use   MeSH
• Kanamycin MeSH
• Capreomycin MeSH
• Humans MeSH
• Pyrazinamide MeSH
• Rifampin administration & dosage   therapeutic use   MeSH
• Streptomycin administration & dosage   therapeutic use   MeSH
• Tuberculosis * drug therapy   MeSH
• Check Tag
• Humans MeSH

We report a case of cavitary pulmonary disease caused by Mycobacterium shimoidei in 67-year-old female with history of asthma. Even though susceptibility testing was not available, choice of treatment regimen (streptomycin, rifampicin, ethambutol, and clarithromycin), based on a few cases with favorable outcome reported in the literature, resulted with an excellent clinical, microbiological, and radiological response. This is the first report of pulmonary disease caused by M. shimoidei, but also the first ever isolation of M. shimoidei in Croatia.

• MeSH
• Anti-Bacterial Agents administration & dosage   MeSH
• Mycobacterium Infections, Nontuberculous drug therapy   microbiology   MeSH
• Clarithromycin administration & dosage   MeSH
• Humans MeSH
• Nontuberculous Mycobacteria drug effects   isolation & purification   physiology   MeSH
• Lung Diseases drug therapy   microbiology   MeSH
• Rifampin administration & dosage   MeSH
• Aged MeSH
• Streptomycin administration & dosage   MeSH
• Treatment Outcome MeSH
• Check Tag
• Humans MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Case Reports MeSH
• Geographicals
• Croatia MeSH

Tuberkulóza (TBC) oka je v krajinách s nízkym endemickým výskytom ochorenie veľmi zriedkavé. Môže sa vyskytovať ako pri orgánovej, tak latentnej tuberkulóznej infekcii alebo úplne izolovane. Pre stanovenie diagnózy potvrdenej očnej tuberkulózy je nevyhnutné dokázať prítomnosť Mycobacterium tuberculosis priamo v očných tkanivách, čo je pri známej paucibacilarite veľmi náročné. V uvedenom článku opisujeme prípad pacienta schoroiditis serpiginosa, u ktorého v rámci diferenciálnej diagnostiky bola odobraná vzorka sklovca na PCR vyšetrenie prítomnosti mykobaktéria tuberkulózy. Po obdržaní negatívneho výsledku ako aj ostatných negatívnych sérologických vyšetreniach bol pacient 33 mesiacov liečený imunosupresívnou liečbu pre neustále recidivujúci charakter ochorenia. Až po vzostupe nešpecifických zápalových parametrov, sérokonverzii Mantoux II a pozitivite IGRA testov napriek negatívnej snímke pľúc a negatívnom mikroskopickom a kultivačnom vyšetrení na prítomnosť Mycobacterium tuberculosis, sme diagnózu konvertovali na predpokladanú tuberkulóznu, serpiginóznej choroiditíde podobnú klinickú jednotku. Pacientovi sme nasadili diagnostickú terapiu antituberkulotikmi s pozitívnou terapeutickou odozvou. Na kompletné zhojenie

Ocular tuberculosis (TB) is very rare in countries with a low endemic occurrence of this disease. It may be present in connection with organ and/or latent tuberculous infection or as an isolated form. A presence of Mycobacterium tuberculosis directly in ocular structures is essential for a diagnosis of proven ocular tuberculosis, which is very demanding due to its known paucibacillary character. A patient with choroiditis serpiginosa, who underwent PCR testing of his vitreous sample for a presence of Mycobacterium tuberculosis during a process of differential diagnosis, is presented in our paper. Based on negative results of both vitreous sample and other serology tests and due to recurrent character of the disease the patient was treated with immunosuppressive therapy for a period of 33 months. Despite negative chest X ray and negative microscopic and culture tests for a presence of Mycobacterium tuberculosis the diagnosis was converted to a suspected tuberculous serpiginous-like chorioditis after the increase of non-specific inflammatory parameters, Mantoux II seroconversion and positivity of IGRA tests. The patient received antituberculous therapy as a diagnostic treatment and had a positive therapeutic response. Complete healing of intraocular inflammation required the administration of the antituberculous therapy for a period of 24 months.

• MeSH
• Antitubercular Agents therapeutic use   MeSH
• Choroiditis * etiology   drug therapy   MeSH
• Diagnosis, Differential MeSH
• Ethambutol administration & dosage   therapeutic use   MeSH
• Immunosuppression Therapy MeSH
• Isoniazid administration & dosage   therapeutic use   MeSH
• Middle Aged MeSH
• Humans MeSH
• Moxifloxacin MeSH
• Mycobacterium tuberculosis isolation & purification   MeSH
• Prednisone administration & dosage   therapeutic use   MeSH
• Rifampin administration & dosage   therapeutic use   MeSH
• Tuberculosis, Ocular * diagnosis   drug therapy   blood   MeSH
• Uveitis drug therapy   surgery   complications   MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Publication type
• Case Reports MeSH

• MeSH
• Antitubercular Agents MeSH
• Antibiotics, Antitubercular MeSH
• Renal Insufficiency, Chronic * complications   MeSH
• Thorax diagnostic imaging   MeSH
• Isoniazid administration & dosage   therapeutic use   MeSH
• Humans MeSH
• Pyridoxine administration & dosage   therapeutic use   MeSH
• Rifampin administration & dosage   therapeutic use   MeSH
• Practice Guidelines as Topic MeSH
• Interferon-gamma Release Tests MeSH
• Tuberculosis * diagnosis   drug therapy   MeSH
• Vitamin B Complex MeSH
• Check Tag
• Humans MeSH

We have developed a biodegradable, biocompatible system for the delivery of the antituberculotic antibiotic rifampicin with a built-in drug release and nanoparticle degradation fluorescence sensor. Polymer nanoparticles based on poly(ethylene oxide) monomethyl ether-block-poly(ε-caprolactone) were noncovalently loaded with rifampicin, a combination that, to best of our knowledge, was not previously described in the literature, which showed significant benefits. The nanoparticles contain a Förster resonance energy transfer (FRET) system that allows real-time assessment of drug release not only in vitro, but also in living macrophages where the mycobacteria typically reside as hard-to-kill intracellular parasites. The fluorophore also enables in situ monitoring of the enzymatic nanoparticle degradation in the macrophages. We show that the nanoparticles are efficiently taken up by macrophages, where they are very quickly associated with the lysosomal compartment. After drug release, the nanoparticles in the cmacrophages are enzymatically degraded, with half-life 88±11 min.

• MeSH
• Antitubercular Agents administration & dosage   MeSH
• Biocompatible Materials chemistry   MeSH
• Drug Delivery Systems * MeSH
• Macrophages drug effects   metabolism   MeSH
• Mice MeSH
• Nanoparticles chemistry   MeSH
• Polyesters chemistry   MeSH
• Polyethylene Glycols chemistry   MeSH
• RAW 264.7 Cells MeSH
• Fluorescence Resonance Energy Transfer MeSH
• Rifampin administration & dosage   MeSH
• Drug Liberation * MeSH
• Animals MeSH
• Check Tag
• Mice MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH